Chronic kidney disease (CKD) presents complex diagnostic and therapeutic challenges due to its heterogeneity and progressive nature. In this webinar, we explore how integrating genetic testing with real-world clinical data is revolutionizing the understanding of kidney disease and unlocking new avenues for targeted drug development.
Join us as we delve into the power of a longitudinal clinicogenomic database purpose-built for kidney disease—capturing genetic variants, clinical outcomes, and patient trajectories over time. Through real-world case studies and emerging research, we'll demonstrate how this integrated approach is enabling earlier and more accurate diagnoses, refining patient identification, and informing precision drug development for CKD.
Whether you're a clinical researcher, drug developer, or healthcare innovator, this session offers a front-row look at how clinicogenomic intelligence is shaping the future of kidney care.
Dr. Ronen Schneider is a clinician-scientist with expertise in the genetic mechanisms of nephrotic syndrome. He trained at Hadassah Hospital in Jerusalem, Israel, where he became an Attending Nephrologist before moving to the U.S. in 2016 for a postdoctoral research fellowship at Boston Children's Hospital (BCH). He most recently had dual roles as an Associate Physician in the Renal Division at Brigham and Women’s Hospital and a Principal Investigator at BCH. His research has focused on the molecular and clinical genetics of chronic kidney disease, leading to the discovery of novel monogenic causes of steroid-resistant nephrotic syndrome. He has co-authored over 40 peer-reviewed publications and led innovative work on gene therapy for glomerular diseases. Dr. Ronen has been actively involved in clinical nephrology, including co-directing the Renal Genetics and PKD Clinic at BWH. Currently, he is the Medical Director of renal genetics at Natera.
Dr. Tabriziani, Natera's Senior Medical Director of Organ Health and Transplantation since 2020, graduated with honors from Iran University of Medical Sciences in 1995. He completed his residency at St. Barnabas Hospital/Weill Cornell and fellowships in Nephrology/Hypertension (Georgetown, chief senior fellow) and Kidney/Pancreas Transplant (UCSF). He established and directed the Pancreas Transplant Program at Westchester Medical Center and later became Associate Professor and Medical Director at Loma Linda University. A principal investigator and published researcher in transplantation, nephrology, and hypertension, Dr. Tabriziani is dedicated to advancing patient care and medical education.
At Advisory Board, our team of nearly 200 experts serves over 4,500 organizations that include hospitals, health systems, post-acute care providers, physician groups, life sciences firms, digital health companies, and health plans.